Merck (MRK) Return on Capital Employed (2009 - 2026)
Merck (MRK) reported Return on Capital Employed of 5.22% for Q1 2026, down 1083.0% year-over-year from 0.53% in Q1 2025, and down 216.93% quarter-over-quarter from 4.47% in Q4 2025.
Merck (MRK) Return on Capital Employed (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Return on Capital Employed data on file, last reported at 5.22% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 5.22%, down 1083.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 5.22% (down 1083.0% YoY), and the FY2025 annual result was 4.75%, down 93.0% from the prior year.
- Return on Capital Employed retreated to 5.22% in Q1 2026 per MRK's latest filing, from 4.47% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 7.54% in Q3 2025 and troughed at 17.58% in Q4 2023.
- A 5-year average of 2.09% and a median of 0.67% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed sank 1642 bps in 2023, then soared 2291 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 1.15% in 2022, then plunged by 1425 bps to 17.58% in 2023, then jumped by 130 bps to 5.34% in 2024, then decreased by 16 bps to 4.47% in 2025, then sank by 217 bps to 5.22% in 2026.
- Business Quant data shows MRK's Return on Capital Employed at 5.22% in Q1 2026, 4.47% in Q4 2025, and 7.54% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 9.49% |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 42.94% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 28.18% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 16.47% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -10.20% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -6.84% |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.22% |
| Dec 31, 2025 | 4.47% |
| Sep 30, 2025 | 7.54% |
| Jun 30, 2025 | 4.74% |
| Mar 31, 2025 | 5.60% |
| Dec 31, 2024 | 5.34% |
| Sep 30, 2024 | -1.82% |
| Jun 30, 2024 | -0.25% |
| Mar 31, 2024 | -14.58% |
| Dec 31, 2023 | -17.58% |
| Sep 30, 2023 | -10.48% |
| Jun 30, 2023 | -12.51% |
| Mar 31, 2023 | -0.85% |
| Dec 31, 2022 | -1.15% |
| Sep 30, 2022 | -0.67% |
| Jun 30, 2022 | 1.91% |
| Mar 31, 2022 | -0.07% |
| Dec 31, 2021 | 0.33% |
| Sep 30, 2021 | -10.76% |
| Jun 30, 2021 | -13.77% |